Home – CDMO Solutions | Viral Vectors | Other vectors
Broad viral vector expertise and infrastructure
Alongside lentivirus, AAV, and adenovirus, OXB also has the expertise and infrastructure to support development and manufacturing of other viral vectors, enabling clients to explore alternative approaches for gene therapy, oncolytic therapies, and vaccines. These additional capabilities broaden the range of options available to our partners and reflect the depth of our viral vector knowledge.
MVA (Modified Vaccinia Ankara) vectors
Through the acquisition of sites in France, OXB has expanded expertise in Modified Vaccinia Ankara (MVA) vectors. MVA has become an important viral backbone for immuno-oncology and infectious disease vaccines, thanks to its ability to elicit strong immune responses and its excellent safety profile.
OXB can support process and analytical development for MVA-based programmes, manufacture GMP-grade MVA vectors for clinical supply, and provide regulatory-compliant CMC packages to support global submissions.
0-12
monthsTo GMP
0E9
pfu/mLMVA drug substance
0
Vials/batch in drug product fill/finish
>0
Successful drug substance and drug product batches
Other poxvirus vectors
Building on our MVA capabilities, OXB can also apply its knowledge to other poxvirus-based vectors, which are increasingly being explored for therapeutic vaccines and novel immunotherapies. Our viral vector expertise, combined with flexible bio manufacturing facilities, enables us to design tailored solutions for poxvirus-based programmes.
Ways to work with us
There are multiple ways in which pharma, biotechs and start-ups work with us, depending on development phase, scale, and individual IP requirements.
Platform project
For clients that are pre-clinical or early-clinical that wish to reach GMP at an accelerated rate with a proven process.
Custom solution
For clients that are pre-clinical or early-clinical that require flexibility in the manufacture of their drug candidate.
Tech-transfer
For clients in phase I, II, or III that need to transfer their manufacture to a CDMO for scale and/or long-term manufacture.
